ProMIS Neurosciences Inc. (PMN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $29.60M
Last updated: Nov 17, 2026 at 4:23 PM ET
ProMIS Neurosciences Inc. (PMN) Stock Chart
ProMIS Neurosciences (PMN) has a latest price of $3.21 on Nov 17, 2026, 88.3% below its 52-week high of $27.40. Its price fell 67.0% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 54.6%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $44,820.54 in Jan 2018 and its lowest $3.31 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart PMN with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for PMN.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 78.1%, and over 6 months it fell 69.9%. The month-end price fell 92.4% over the 3 years through Oct 2026, a compound annual decline of 57.7%.
| Period | Change |
|---|---|
| 1 month | -61.0% |
| 3 months | -78.1% |
| 6 months | -69.9% |
| 12 months | -67.0% |
| 12 months, with dividends | -67.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -92.4% | -57.7% |
| 5 years | -100.0% | -81.0% |
| 10 years | -100.0% | -54.6% |
Price by Year
Its best calendar year was 2017, when the price rose 66.7%, and its weakest was 2022, when it fell 98.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.31 | -51.5% |
| 2025 | $6.83 | -71.2% |
| 2024 | $23.70 | -17.6% |
| 2023 | $28.75 | -73.5% |
| 2022 | $108.50 | -98.9% |
| 2021 | $9,860.52 | +32.7% |
| 2020 | $7,431.25 | -36.2% |
| 2019 | $11,653.34 | -34.6% |
| 2018 | $17,829.61 | +17.0% |
| 2017 | $15,238.98 | +66.7% |
Trading Range
The price is 63.5% below its 50-day average of $8.80 and 74.3% below its 200-day average of $12.49.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $3.21 | |
| 52-week high | $27.40 | -88.3% |
| 52-week low | $2.78 | +15.5% |
| 50-day average | $8.80 | -63.5% |
| 200-day average | $12.49 | -74.3% |
Price Risk
Over 3 years, its largest fall from a peak was 95.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.99 |
| Largest fall, 1 year | -87.9% |
| Largest fall, 3 years | -95.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About PMN
What is PMN's 1-year price change?
ProMIS Neurosciences's price fell 67.0% over the past 12 months. With dividends included, the 12-month total return was -67.0%.
What is PMN's 5-year price change?
ProMIS Neurosciences's month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 81.0%. These figures leave out dividends.
What is PMN's 52-week high and low?
ProMIS Neurosciences's 52-week high is $27.40 and its 52-week low is $2.78. Its latest price of $3.21 on Nov 17, 2026 is 88.3% below the high.
What is PMN's beta?
ProMIS Neurosciences's 1-year beta against the S&P 500 is 1.99, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 87.9%.
Is the PMN chart free?
Yes. Advanced Charting for PMN is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
PMN pages: Overview, Charting, Earnings, Forecast, Statistics, Competitors